News

Last year, Sarepta – which leads the market for exon-skipping DMD drugs – got FDA approval for Elevidys (delandistrogene moxeparvovec), the first gene therapy for the muscle-wasting disease.
The EMA has called a temporary halt to a phase 2 trial of Sarepta's Roche-partnered Duchenne muscular dystrophy (DMD) gene therapy Elevidys in the wake of the death of a patient who received the ...
Though subsequent remedial measures are most commonly associated with product liability litigation, New York courts apply this doctrine in other types of litigation as well, often in creative ways ...
This paper presents an algorithm for automatic load shedding as a Remedial Action Scheme (RAS) for power oscillation damping. The algorithm computes the exact amount of power for the load shedding in ...